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Abstract Urinary tract infections (UTI) are common in
childhood. Presence of pyuria and bacteriuria in an
appropriately collected urine sample are diagnostic of
UTI. The risk of UTI is increased with an underlying
urological abnormality such as vesicoureteral reflux, con-
stipation, and voiding dysfunction. Patients with acute
pyelonephritis are at risk of renal scarring and subsequent
complications such as hypertension, proteinuria with and
without FSGS, pregnancy-related complications and even
end-stage renal failure. The relevance and the sequence of
the renal imaging following initial UTI, and the role of
antimicrobial prophylaxis and surgical intervention are
currently undergoing an intense debate. Prompt treatment
of UTI and appropriate follow-up of those at increased risk
of recurrence and/or renal scarring are important.
Keywords Urinary tract infection.Vesicoureteric reflux.
Management
Introduction
Urinary tract infection (UTI) is a common illness in
children, with overall prevalence ranging from 2% to 8%
throughout childhood [1–3]. It can be associated with long-
term sequela of renal scarring, which may cause hyperten-
sion, proteinuria, pregnancy-related complications, or even
progressive renal failure. The risk of recurrent UTI in
children has been estimated to be 12–30% in the first
6–12 months after the initial UTI [4, 5]. Predisposing
factors for recurrence include vesicoureteral reflux and
dysfunctional elimination [6–8].Escherichia coli remains
the most common organism causing UTI in children (60–
92%). Other common organisms include Klebsiella, Prote-
us, Enterococcus, and Enterobacter spp. [9–11]. Less
common organisms such as Pseudomonas, Group B
Streptococcus, and Staphylococcus aureus are seen with
increased frequency in patients with anatomical defects,
kidney stones, following genitourinary surgery or bladder
catheterization, and following repeated courses with antibi-
otic treatments [3, 8]. The pathogenetic mechanism of UTI
is thought to be an ascending infection from periurethral
organisms in children older than the neonatal period.
Factors contributing to infection include bacterial virulence
factors as well as host defense mechanisms. Clinical
differentiation of the site of UTI is important. Pyelonephri-
tis, or upper UTI, refers to infection of the renal
parenchyma, which manifests as flank pain, fever, and
systemic manifestations such as nausea, vomiting, or
diarrhea. These patients are at risk of renal scarring.
Cystitis, or lower UTI, is infection of the urinary bladder,
which usually presents with symptoms of bladder irritation,
dysuria, urinary frequency or hesitancy, and low-grade
abdominal pain in the absence of systemic manifestations
such as fever. Clinical manifestations of UTI are also age
dependent. Apart from fever, older children can express and
localize flank pain associated with pyelonephritis compared
with infants with pyelonephritis, who may present with a
combination of symptoms that include fever, irritability,
excessive crying, diarrhea, and poor feeding. In young infants
S. A. Saadeh
Pediatric Nephrology and Hypertension, Children’s Hospital
of Michigan, Wayne State University,
Detroit, MI, USA
T. K. Mattoo (*)
Children’s Hospital of Michigan, Pediatric Nephrology and
Hypertension, Wayne State University School of Medicine,
3901 Beaubien St,
Detroit, MI 48201, USA
e-mail: tmattoo@med.wayne.edu
EDUCATIONAL REVIEW
Managing urinary tract infections
Sermin A. Saadeh & Tej K. Mattoo
Received: 1 October 2010 /Revised: 25 January 2011 /Accepted: 28 January 2011 /Published online: 16 March 2011
Pediatr Nephrol (2011) 26:1967–1976
DOI 10.1007/s00467-011-1801-5and children, fever is of special importance as a clinical
marker of renal parenchymal involvement (pyelonephritis).
As acknowledged by the American Academy of Pediatrics
(AAP) in its practice parameters, the presence of high fever
(≥39°C) with clinical diagnosis of UTI is an important
indicator of pyelonephritis compared with no fever (≤38°C)
in those with cystitis [12, 13]. Indirect tests of inflammation
[elevated peripheral white blood cell (WBC) count, elevated
C-reactive protein (CRP)] can provide helpful guidance. The
use of dimercaptosuccinate (DMSA) scan to differentiate the
site of infection is discussed separately.
Diagnosing UTI requires appropriate collection of
uncontaminated urine sample for analysis and culture. The
technique of obtaining the urine can affect sample quality. It
is recommended to collect urine by clean catch in children
who are toilet trained. In infants and younger children,
urine should be obtained by urinary catheterization or
suprapubic aspiration. Collection of urine with adhesive
bags to the perineal area has no role in diagnosing UTI due
to the high risk of contamination. For a prompt diagnosis,
urine is examined by dipstick and microscopy. Urine
dipstick is an inexpensive and a readily available technique.
The presence of either leukocyte esterase (LE) and/or nitrite
is interpreted as a positive dipstick test [14], whereas blood
and protein are poor indicators of UTI. Urine microscopy is
performed to look for the presence of WBC or bacteria, and
its sensitivity and specificity are better with uncentrifuged
urine and Gram staining of the sample. Urine Gram stain
for bacteria has a better sensitivity (91%) and specificity
(96%) than all other rapid tests used alone or in
combination [14] and when positive can guide therapy in
children suspected of having UTI. When uncentrifuged
urine is examined microscopically, pyuria is defined by≥10
WBC/mm
3 and bacteriuria by the presence of any bacteria
per 10 oil immersion field of Gram-stained smear. Table 1
summarizes data from a recent meta-analysis by Williams
et al. [14] evaluating rapid urine tests and comparing the
accuracy of dipstick with microscopy. They concluded that
Gram stain is the single best rapid test but still cannot replace
urine culture. The study also concluded that either LE or
nitrite positivity can be interpreted as positive dipstick testing.
Urine culture remains the reference standard for diag-
nosing UTI. However, because it requires a minimum of 18
hours before a result is known, the rapid tests are often used
to guide the initial management. Accepted colony count
criteria for a probable UTI diagnosis are summarized in
Table 2 [15, 16]. Increasing the acceptable colony count for
UTI diagnosis has been suggested to decrease the false
positive rate [17].
Asymptomatic bacteriuria
Asymptomatic bacteriuria (ABU) is defined as the growth
of a significant number of a single organism [often>
100,000 colony-forming units (CFU)/ml] from a urine
sample of an asymptomatic child with no pyuria. It is often
an incidental finding and can be demonstrated on repeat
urine cultures. The bacterium isolated is most often an E.
coli strain of low virulence that colonizes the urinary tract
and does not have significant ability to damage the kidneys
[18]. Antibiotics should not be given to eradicate ABU
[19–22]. ABU is also observed in children with neurogenic
bladder, particularly if the patient is on clean intermittent
catheterization, but studies have not shown increased risk of
renal scarring or the need for prophylactic antibiotics in this
group [19]. Patients with neurogenic bladder very often
also have increased number of WBC in their urine, which
makes UTI diagnosis difficult.
Renal imaging in UTI
The rationale for renal imaging is to identify risk factors
and abnormalities of the genitourinary tract that can be
modified to decrease the likelihood of recurrent UTI and
renal scarring.
Renal ultrasound
Renal ultrasound is useful for detecting renal abscess,
hydronephrosis, congenital abnormalities, and sometimes
stones. It has a lower sensitivity for diagnosing pyelone-
phritis than DMSA; abnormalities compatible with pyelo-
nephritis were reported in 20–69% of patients by ultrasound
compared with 40–92% by DMSA [23]. Ultrasound has
limited usefulness for assessing the presence of renal
scarring; a study by Ahmed et al. [24] showed that renal
Table 1 Sensitivity and specificity of rapid urine tests. Adapted with modification from [14], with permission
WBC Gram stain LE Nitrite Either LE or nitrite Both LE and nitrite
Sensitivity 74% 91% 79% 49% 88% 45%
Specificity 86% 96% 87% 98% 79% 98%
WBC white blood cells, LE leukocyte esterase
1968 Pediatr Nephrol (2011) 26:1967–1976ultrasound is not as sensitive in comparison with DMSA
scan when used to detect renal scarring in children being
worked up for hypertension.
Voiding cystourethrogram
Voiding cystourethrogram (VCUG) is the main diagnostic
modalityforidentifyingvesicoureteralreflux(VUR).Itcanbe
performed immediately after antibiotic treatment is completed
and the patient is asymptomatic. It requires urinary catheter-
ization. VUR grading has been suggested by the International
Reflux Study (IRS) into 5 grades [25]. This grading system
has been used in an effort to predict the outcome of children
with different grades of reflux, standardize management, and
compare outcomes of different management approaches.
Radionuclear cystography (RNC) has been primarily used to
reduce radiation exposure for children during follow-up for
VUR or after surgical correction to verify resolution.
However, tailored low-dose fluoroscopic VCUG can result
in gonadal radiation exposure comparable with that reported
with the radionuclide technique. RNC grades VUR into
mild, moderate, and severe. Therefore, because of its
inability to grade VUR or reveal anatomic defects, it is not
used as an initial test to diagnose VUR.
DMSA (dimercaptosuccinic acid) renal scan
DMSAisthegoldstandardfordiagnosingacutepyelonephritis
and renal scars. When used at the time of acute illness, it can
helpconfirmacutepyelonephritis,ifindoubt.However,itdoes
not distinguish lesions that will spontaneously resolve from
those which will cause renal scarring. Also, the differentiation
of changes secondaryto acute pyelonephritis fromthose due to
preexisting renal scars can be difficult. For these reasons, a
delay of 4–6 months is needed following acute pyelonephritis
to allow acute reversible lesions to resolve in order to diagnose
renal scarring [26].
Rationale for imaging
The best approach for imaging studies in children with UTI
is debatable because of the doubtful evidence and concerns
over the actual value of these studies in altering the
management and final outcome. The AAP, in its practice
parameters published in 1999, recommends renal ultra-
sound and VCUG or RNC be performed in any infant or
child (2 months to 2 years of age) after a first UTI [12]. In
2007, in an effort to reduce the imaging burden of UTI
work-up, the National Institute for Health and Clinical
Excellence (NICE) of Great Britain published its recom-
mendations on a more selective approach for renal imaging
after UTI [27]. These recommendations are primarily based
on patient age, response to antibacterial treatment, and
typical versus atypical UTI. Further details on the guide-
lines are shown in Table 3. However, an argument has been
made that this very selective approach can lead to delayed
diagnosis of VUR and congenital abnormalities in these
children [28, 29]. A retrospective analysis by Tse
et al. revealed that selective imaging by NICE guidelines
would have left a significant number of undiagnosed VUR
and renal scars in infants <6 months of age [30]. More
studies are needed to validate the NICE guidelines.
Another suggested approach to imaging in VUR is to
replace the VCUG with a DMSA scan from the top-down
approach; VCUG can then be performed if ultrasound and
DMSA are abnormal [31, 32]. However, it has been shown
recently that DMSA scan has limited ability in diagnosing
VUR and replacing VCUG for evaluating children with
their first UTI. Furthermore, the issue of differences in
methodology used by different medical centers and the
interobserver variability in scan interpretation need to be
kept in mind [33]. A more definitive answer to the question
of imaging is still lacking, and more evidence is needed to
validate any of the current suggested approaches. The
treating clinician should be aware of the available renal
imaging options and their appropriate use in a particular
child, which depends on patient age, VUR severity,
presence or absence of renal scarring, and UTI frequency.
UTI treatment
UTI treatment depends on infection location (cystitis vs.
pyelonephritis), patient’s age, severity of presentation, and
Collection method Colony count (CFU/ml) Probability of infection (%)






Clean-catch, midstream urine >10
4 (boy) Infection likely
≥10
5 (girl) (3 specimens) 95%
≥10
5 (girl) (2 specimens) 90%
≥10
5 (girl) (1 specimen) 80%
Table 2 Diagnosing urinary
tract infection (UTI) by urine
culture
CFU colony-forming units
Adapted with modification from
[16], with permission
Pediatr Nephrol (2011) 26:1967–1976 1969the antimicrobial resistance pattern in the community.
Empiric therapy for UTI should be initiated after
appropriate urine specimen for culture has been obtained.
Children <24 months of age suspected to have UTI should be
treated as having pyelonephritis, whereas a more symptom-
based approach can be followed in older children.
Treatment promptness
It is believed that prompt antibiotic treatment of UTI
diminishes the risk of renal scarring [12, 34]. However, two
recent studies, by Hewitt et al. [35] and Doganis et al. [36],
demonstrated that early treatment (< 1 day of fever) of
acute pyelonephritis in infants and young children had no
significant effect on the incidence of subsequent renal
scarring when compared with children treated after 24 h.
However, Doganis et al. showed that early and appropriate
treatment, especially during the first 24 h after symptom
onset, may diminish the likelihood of renal involvement
during the acute phase of the infection [36]. The study
included a smaller number of patients treated after 4 days
compared with patients treated in <1 day. Also, it should
still be kept in mind that even though these studies showed
no evidence of renal damage following delayed treatment, it
is not advisable to delay treatment of a sick patient when
UTI is diagnosed. Patients with pyelonephritis can have
complications other than scarring when treatment is
delayed, such as sepsis and abscess formation.
Oral versus parenteral therapy
The AAP practice parameter guidelines published in 1999
recommend that well-appearing children between 2 months
and 2 years of age with UTI can be treated with orally or
parenterally administered antibiotics [12]. A 2007 Cochrane
Review of 23 randomized and quasirandomized controlled
studies showed no significant difference in persistent
kidney damage at 6–12 months or in fever duration
between orally administered antibiotic therapy for 10–
14 days and intravenously administered (IV) antibiotic
therapy for 3 days followed by oral therapy for 10 days.
Also, no significant difference in persistent kidney damage
was found between initial IV therapy (3–4 days) followed
by oral therapy and IV therapy for the entire treatment
duration (7–14 days) [37]. Few other studies had similar
conclusions when oral antibiotics were compared with
parenteral therapy. A multicenter randomized controlled
trial by Montini et al. showed that oral therapy was as
effective as IV therapy followed by oral therapy for
managing the first UTI episode [38]. However, most of
these studies excluded high-risk children, such as those
with significant renal scarring or genitourinary abnormali-
Antibiotic Dose
Trimethoprim (TMP)-sulfamethoxazole 8 mg (TMP)/kg/day divided every 12 h
Nitrofurantoin 5-7 mg/kg/day divided every 6 h
Amoxicillin 25-45 mg/kg/day divided every 12 h
Amoxicillin-clavulanate 25-45 mg (amoxicillin)/kg/day divided every 8-12 h
Cephalexin 25-50 mg/kg/day divided every 6 h
Cefixime 8 mg/kg/day divided every 12 h
Table 4 Oral antibiotics for
treating cystitis
Table 3 National Institute for Health and Clinical Excellence (NICE) imaging guidelines
Responds well to treatment within 48 h Atypical UTI
a Recurrent UTI
b
Age < 6 months Ultrasound
c Ultrasound, DMSA and VCUG Ultrasound, DMSA and VCUG
Age 6 months–3 years None Ultrasound and DMSA
d Ultrasound and DMSA
d
Age > 3 years None Ultrasound Ultrasound and DMSA
UTI urinary tract infection, DMSA dimercaptosuccinate, VCUG voiding cystourethrogram
aNon-Escherechia coli UTI: seriously ill, poor urine flow, abdominal or bladder mass, raised creatinine, septicemia, failure to respond to treatment with
suitable antibiotics within 48 h
bTwo or more episodes of UTI with acute pyelonephritis/upper urinary tract infection, or
one episode of UTI with acute pyelonephritis/upper urinary tract infection plus one or more episode of UTI with cystitis/lower urinary tract
infection, or
three or more episodes of UTI with cystitis/lower urinary tract infection
cIf ultrasound is abnormal, consider a VCUG
dConsider VCUG if dilatation on ultrasound, poor urine flow, non-E. coli infection, family history of VUR
1970 Pediatr Nephrol (2011) 26:1967–1976ties. These high-risk children need to be identified and
might benefit from initial parenteral therapy. In general,
orally administered antibiotics can be used effectively on an
outpatient basis to treat acute pyelonephritis in children
>2–3 months who are clinically stable [37, 39]. Suitable
antibiotic choices are listed in Table 5. For lower UTI
(cystitis), orally administered antibiotics for a short period
(2–4 days) are generally effective.
Indications for hospitalization of any child with UTI
include clinical urosepsis, laboratory evidence of bacter-
emia, immunocompromised patient, intolerance to oral
intake, lack of adequate outpatient follow-up, or failure to
respond to outpatient therapy. Managing febrile infants
<2–3 month has not been well studied because these
patients are often excluded from randomized controlled
trials. They have a 10% concomitant risk of bacteremia
[36], which prompts hospitalization and IV treatment with
antibiotics until the systemic signs have resolved [3, 40,
41]. Complete septic work-up should be done in patients
<1 month because UTI is most often secondary to
hematogenous seeding rather than ascending infection.
Antibiotic selection
The choice of empirical antibiotics is guided by local
resistance patterns, but coverage for E. coli as the most
common infective organism should be considered. The
North American Urinary Tract Infection Collaborative Trial
report published in 2006 showed considerable E. coli
resistance to β-lactam antibiotics (37.7%) and trimetho-
prim–sulfamethoxazole (21.3%) [42], which makes these
agents inadequate first-line choices for treating serious UTI
[43, 44]. Prelog et al., in a retrospective study of children
with febrile UTI, showed that β-lactam antibiotics and
trimethoprim-resistant E. coli were more commonly seen in
children with (35.8%) than in those without (25.8%) VUR
[44]. However, E. coli remains largely sensitive to third-
generation cephalosporins (ceftriaxone, cefixime), amino-
glycosides, and nitrofurantoin [43, 45]. Final antibiotic
choice should be based on pathogen identification and
sensitivity from urine culture. In infants <1 month, the most
likely pathogens are E. coli and E. faecalis, which require
empiric therapy with a β-lactam antibiotic and an amino-
glycoside.
Orally administered antibiotics Second- and third-
generation cephalosporins are appropriate first-line treat-
ment options for pyelonephritis. Alternatively, amoxicillin–
clavulanate, trimethoprim–sulfamethoxazole (TMP-SMX),
and first-generation cephalosporins can be used with
caution due to increasing resistance of E. coli. Fluoroqui-
nolones (ciprofloxacin) are effective for E. coli but should
not be used as first-line agents due to their questionable
safety in children. Ciprofloxacin should be reserved for UTI
caused by P. aeruginosa or other multi-drug-resistant
organisms.
Parenteral therapy Third- or fourth-generation cephalo-
sporins and aminoglycosides are appropriate for empiric
treatment. When enterococcal UTI is suspected (urinary
catheter, instrumentation of the urinary bladder, or genito-
urinary abnormalities), ampicillin should be included in
treatment options. Gentamicin can be used parenterally as
an adjunctive treatment in resistant organisms. However, its
nephrotoxic properties limit its use. When gentamicin used,
therapeutic levels and kidney function should be monitored
(Table 6). After urine culture results are available, antibiotic
treatment could be adjusted according to the sensitivity of
the identified pathogen.
Treatment duration and response
The optimal treatment duration for pyelonephritis is
7–14 days, depending on administration route. In cases of
severe pyelonephritis (acute lobar nephronia), prolonged
parenteral therapy may help prevent progression to abscess
[1]. For treating acute bacterial cystitis, several studies have
shown that short treatment courses of 2–4 days are as
effective as 7–14 days in eradicating lower UTI in children
[46]. Treatment response in most patients is often noted
within 24–48 h of antibiotic initiation. Children with
worsening clinical condition (other than fever) might need
imaging to rule out abscess formation, urinary stones, or
obstruction. Revising the antibiotic selection might be
needed. Repeat urine cultures after treatment are not needed
in children who show clinical response to treatment [47,
48]. Children on prophylactic antibiotics for VUR might
present a challenge to treatment as they are more likely to
Antibiotic Dose
Cefixime 8 mg/kg/day divided every 12 h
Cefdinir 14 mg/kg/day divided every 12 h
Amoxicillin-clavulanate 25-45 mg (amoxicillin)/kg/day divided every 8-12 h
Ciprofloxacin 20-30 mg/kg/day divided every 12 h
Table 5 Orally administered
antibiotics for treating
pyelonephritis
Pediatr Nephrol (2011) 26:1967–1976 1971haveUTIwitharesistantorganism[11, 49]. This is especially
the case when prophylactic cephalosporins are used. Resis-
tance has also been found to third-generation antibiotics in
these children, but sensitivity to gentamicin remained high.
This should be considered when choosing an antibiotic for
these children, especially those who are acutely ill or not
responding to initial empiric therapy. Children with anatom-
ical defects, following genitourinary surgery, or repeated UTI
and antibiotic courses, are more likely to have other
causative organisms, such as Pseudomonas,G r o u pB
Streptococcus, S. aureus,o rS. epidermidis, which should
also be taken into consideration when these patients do not
respond adequately to initial empiric therapy.
Antimicrobial prophylaxis
The role of VUR in causing UTI and the use of antimicrobial
prophylaxis to prevent UTI with and without VUR is
controversial.Regardless,theuseofantimicrobialprophylaxis
has been a standard practice for many decades. In 2006, a
Cochrane Review by Williams et al. [50]i d e n t i f i e de i g h t
randomized studies (618 children) that compared antibiotics
with placebo or no treatment to prevent recurrent UTI. This
analysis showed that antibiotics decreased the risk of positive
urine culture compared with placebo. However, the authors
concluded that more evidence in the form of properly
randomized double-blinded trials is needed to support the
routine use of antibiotic prophylaxis in preventing recurrent
UTI. Recently, there have been six randomized trials on
antimicrobial prophylaxis for UTI [51–56], Table 7. Three of
those included children with and without VUR [51, 54, 55].
Overall, these studies included patients from 0 to 18 years of
age, with grades I–V VUR, if present. Garin et al.[51]a n d
Montini et al.[54] reported no benefit with prophylaxis in
children with and without VUR (grades I–III). The third
study, by Craig et al. [55], which was placebo-controlled,
showed a reduction in the absolute risk of UTI (6 percentage
points) that did not vary with any stratifying variable (age,
sex, reflux status, history of more than one UTI, or
susceptibility of the causative organism for TMP-SMX).
The other three randomized trials of antimicrobial prophy-
laxis for UTI included only patients with VUR grades I–IV,
and patients’ ages ranged from 0 to 3 years [52, 53, 56].
Roussey et al.[52] found no benefit to antibiotic prophylaxis
in low-grade VUR except in boys with grade III reflux.
Pennesi et al. [53] found no difference in UTI recurrence
between prophylaxis and no prophylaxis in all patients
<30 months. The Swedish Reflux Trial [56] studied 203
children (1–2 years of age) with grades III–IV reflux openly
randomized into three groups: low-dose antibiotic prophylaxis,
endoscopic therapy, and surveillance. The study demonstrated
that UTI recurrence rate in girls >1 year with dilating VUR was
higher than in boys and that this rate can be decreased with
antibiotic prophylaxis and endoscopic treatment. There was no
difference between the prophylaxis and endoscopic treatment
groups.Fifty-sevenpercentofpatientsinthe surveillancegroup
suffered a UTI recurrence during follow-up. The study also
showed that girls had a significantly higher rate of new renal
damage on DMSA than boys at 2 years. Renal damage was
most common in the surveillance group and showed a strong
association with recurrent febrile UTI [57]. The results of these
studies should be interpreted with caution because of some
design-related limitations.
In 2007, NICE published its recommendations that health-
care professionals in the United Kingdom do not use antibiotic
prophylaxis routinely in infants and children following first-
time UTI, and only selectively in recurrent UTI [27]. The
Table 6 Parenteral antibiotics for treating pyelonephritis
Antibiotic Dose
Ampicillin 100 mg/kg/day divided every 6 h
Cefotaxime 100-200 mg/kg/day divided every 8 h
Ceftriaxone 50-100 mg/kg/day divided every 12 h
Cefepime 100 mg/kg/day divided every 12 h
Gentamicin 7.5 mg/kg/day divided every 8 h
Table 7 Randomized trials on antimicrobial prophylaxis for urinary tract infections (UTI)
Author and year Patient age Total number of
patients in study
VUR status Number of patients
with VUR
VUR grade Follow-up (months)
Garin et al. [51] 1 month-18 years 218 ±VUR 113 I-III 12
Roussey-Kesler et al. [52] 1 month-3 years 225 +VUR 225 I-III 18
Pennesi et al. [53] 0-30 months 100 + VUR 100 II_IV 24- 48
Montini et al. [54] 2 months-7 years 338 ±VUR 128 I-III 12
Craig et al. [55] 0-18 years 576 ±VUR 243 I-V 12
Swedish Reflux Trial [56] 1-2 years 203 +VUR 203 III-IV 24
VUR vesicoureteral reflux
1972 Pediatr Nephrol (2011) 26:1967–1976American Urological Association (AUA) published its guide-
lines on primary VUR management in September of 2010
based on the current evidence related to VUR management in
children [6]. These guidelines are summarized in Tables 8, 9,
and 10. The initial management of a child with VUR (Tables 8
and 9) is stratified by age, with a more conservative approach
in children <1 year because of their increased morbidity with
pyelonephritis and higher incidence of renal scarring. The
statements made by AUA are graded with respect to the
degree of flexibility in application. Standard is the most rigid
statement policy; Recommendation has significantly less
rigidity, being a statement with sufficient evidence to advocate
for a particular clinical approach; Option offers the most
flexibility when there is evidence of relatively equal strength
to support more than one approach.
In view of all these studies and recommendations,
VUR management is a subject of constant debate. The
need for higher-quality evidence to guide management is
increasing. The Randomized Intervention for Children
with Vesicoureteral Reflux (RIVUR) funded by the US
National Institutes of Health (NIH) is underway. It is a
double-blind, randomized, placebo-controlled trial that
started enrolling in 2007, which will evaluate the role of
antimicrobial prophylaxis in children with grades I–IV
VUR diagnosed after febrile UTI. Until more evidence-
based practices evolve, the treating physician should be
cautious when treating children with risk factors for
recurrent UTI, including VUR. The clinician must decide
whether the benefit of antibiotic use outweighs the risk
and when surgical intervention might be a preferred
option.
Prophylactic antimicrobial choice
Antibiotics commonly used include TMP-SMX, trimetho-
prim, nitrofurantoin, and first-generation cephalosporins.
Amoxicillin can be used in children <2 months, because
TMP-SMX is contraindicated in this age group (Table 11).
Prophylaxis limitations
Antimicrobial resistance is a major concern with antibi-
otic prophylaxis. Cheng et al. [49], in a retrospective
analysis, found that infection was less common in children
on antibiotic prophylaxis compared with their initial
episodes of UTI. Cephalosporins as prophylactic anti-
biotics compared with TMP-SMX are more likely to be
associated with breakthrough UTI caused by extended-
spectrum β-lactamase-producing organisms [49]. This
could present as a problem of increasing difficulty of
prescribing appropriate antibiotics when children present
with recurrent UTI. Other problems with prophylaxis
include compliance and parental concern over long-term
antibiotic administration.
Surgical treatment of VUR
Surgical treatment is usually reserved for patients with
high-grade VUR, recurrent UTI despite antibiotic prophy-
laxis, and noncompliance with prophylactic antibiotics.
Open surgery has largely been replaced by endoscopic
and laparoscopic techniques. Endoscopic treatment involv-
ing subureteral or intraureteral injection of a bulking agent
with dextranomer/ hyaluronic acide (Deflux®) is suggested
as first-line treatment. Success rates are 98.1% for open and
83% for endoscopic surgery after injection [6]. The most
recent AUA guidelines gave the option of surgical
intervention, including open and endoscopic surgery, at
the time of the initial diagnosis. The decision is affected by
the patient’s age, kidney status, reflux grade, and parental
wishes [6]. The Swedish Reflux Trial report on VUR
outcome demonstrated that endoscopic treatment resulted in
a significantly higher resolution or downgrading of dilating
VUR compared with prophylaxis and surveillance [58]. It
also raised concern over the common reappearance of
dilating VUR after 2 years from endoscopic treatment.
Continuous antibiotic prophylaxis
Standard Recommended Option
VUR diagnosed after febrile UTI All grades – ✓ –
VUR diagnosed through screening Grades I & II –– ✓
Grades III- V – ✓ –
Table 8 Initial management of





Table 9 Initial management of a child >1 year old with vesicoureteral




No recurrent febrile UTI,
BBD or renal cortical
anomalies
–– ✓
Recurrent febrile UTI, BBD,
or renal cortical anomalies
– ✓ –
BBD bladder and bowel dysfunction
Pediatr Nephrol (2011) 26:1967–1976 1973Conclusion
UTI is a common infection in children, with a potential
risk for complications such as renal scarring. Appropriate
UTI diagnosis and management is important. Manage-
ment is aimed at treating the acute episode as well as
preventing recurrences. Renal ultrasound after a first UTI
is helpful in diagnosing some underlying congenital
abnormalities that increase recurrence risk and that may
need surgical intervention. VCUG and the DMSA renal
scan remain the gold standards for diagnosing VUR and
renal scarring, respectively. Decisions regarding antimi-
crobial prophylaxis or surgical intervention in children
with VUR are primarily based on patient age, VUR
severity, presence of renal scarring, UTI frequency, and
voiding dysfunction.
Multiple-choice questions
(Answers appear following the reference list)
1. Which one of the following statements regarding UTI
diagnosis is true?
a. Clean-catch urine sample can be used in all children
b. Uretheral catheterization or suprapubic aspiration
should be performed in infants and newborn
c. Uretheral catheterization has a lower likelihood
of contamination compared with suprapubic
aspiration
d. Periuretheral adhesive bag can be used in boys but
not girls because of contamination risk
e. Any bacterial growth from a catheterized urine
sample is considered significant




c. Protein and blood
d. LE and nitrite
e. Protein and LE
3. Which one of the following characterizes asymptomatic
bacteriuria?
a. Pyuria is present
b. Most commonly caused by Pseudomonas Aeruginosa
c. Antibiotic treatment is indicated
d. Can be a normal finding in children with neurogenic
bladder
e. Increased risk of scarring if antibiotic prophylaxis is
not used
4. Which of the following tests is the current gold standard
for diagnosing renal scarring?
a. Ultrasound examination
b. Intravenous pyelography
c. DMSA renal scan
d. CT scan
e. Radionuclear cystography (RNC)
Table 10 Breakthrough urinary tract infection (BT-UTI) management according to American Urological Association (AUA) guidelines
Clinical scenario Recommendation (R)/ Option (O)
Symptomatic BT-UTI R: Change of therapy guided by scenario
Patient on CAP with febrile BT-UTI R: Consider open or endoscopic surgical intervention
Patient on CAP with single febrile BT-UTI without evidence of existing or new
renal cortical abnormalities
O: change to alternative antibiotics is an option before
surgical intervention
Patient not on CAP with febrile BT-UTI R: Initiation of CAP
Patient not on CAP with nonfebrile UTI O: Initiation of CAP
All patients with BT-UTI O: Surgical intervention
CAP continuous antibiotic prophylaxis
Table 11 Prophylactic antimicrobial agents
Antibiotic Dose
Trimethoprim (TMP)–sulfamethoxazole 2 mg TMP/kg/day daily
Nitrofurantoin 1-2 mg/kg/dose daily
Cephalexin 10 mg/kg/dose daily
Amoxicillin 10 mg/kg/dose daily
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Answers:
1. b. Uretheral catheterization or suprapubic aspiration should be
performed in infants and newborn
2. d. LE and nitrite
3. d. Can be a normal finding in children with neurogenic bladder
4. c. DMSA renal scan
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